The Blavatnik Fund for Innovation at Yale Showcase
Presented by the Office of Cooperative Research, Yale University
Thursday, September 17, 2020
1:00 PM to 2:30 PM
Join us as we kick off the 5th year of the Blavatnik Fund for Innovation at Yale. Along with support from Demy-Colton, this webinar will explore where several past award recipients are with their projects, and you will also have the chance to see the latest Blavatnik Awardees and learn how to get involved in the 2020/21 award year.
Blavatnik Showcase Agenda:
Welcome Remarks: Bill Wiesler, PhD, MBA, Director of New Ventures & Director of Blavatnik Fund for Innovation at Yale
Blavatnik Project Updates
Moderator: Sara Demy, Founder & CEO, Demy-Colton
Investigator: Naftali Kaminski, MD
Project: Thyroid Hormone Mimetics for Pulmonary Fibrosis and COVID-19 respiratory disease.
Investigator: Anton Bennett, PhD
Project: Allosteric Inhibition of MKP5 for Treatment of Lung Fibrosis.
Investigator: Anna Pyle, PhD & Founder
Project: Intron Therapeutics is developing a new class of potent antifungal drugs with low toxicity in humans.
Investigator: Jeffrey Bender, MD, & Founder
Project: TargetSite Therapeutics - a novel approach to RNA-targeting has yielded an anti-inflammatory molecule as a first example of the power of the platform.
Investigator: Andrew Miranker, PhD, & Founder
Project: Pangolin Therapeutics seeks to address Multiple System Atrophy (MSA), an aggressive, rare form of Parkinson's for which there are no approved therapeutics.
Investigator: Anna Marie Pyle, PhD, & Founder and Akiko Iwasaki, PhD, Founder (Presenter)
Project: RIGImmune is researching Rig-I agonists as next-generation immunotherapies for cancer.
Investigator: Paul Turner, PhD, & Founder
Project: Felix Biotechnology, Inc. is dedicated to commercial development of bacterio phage (bacteria-specific viruses) as FDA-approved drugs, initially via clinical trials to prove phage can be standard-of-care in protecting cystic fibrosis lungs.
Investigator: Aaron Ring, MD, PhD, & Founder
Project: Simcha Therapeutics is developing a variant of IL-18 designed to thwart a resistance mechanism in tumors.
2019/20 Winners Announcement: Mike Crair, PhD, Vice Provost for Research, Office of the Provost
2020/21 Program Kickoff & Closing Remarks: Morag Grassie, PhD, Associate Director of Blavatnik Fund for Innovation at Yale
Breakout Sessions: Join an individual meeting at 2:30 pm ET immediately follow to meet the presenters and/or hear more about partnering or investing. ***Links to be provided at the webinar.
The Blavatnik Fund for Innovation at Yale is made possible by a grant from The Blavatnik Family Foundation.